S. Khanani

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial

S. Green, K. Jordan, B. Rapoport, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Elotuzumab-based maintenance therapy following autologous stem cell transplant in multiple myeloma deepens post-transplant responses.

M. Ramanathan, Jonathan M Gerber, A. Siddiqui, 2020, Blood cells, molecules & diseases.

Abstract P6-11-11: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer receiving moderately emetogenic chemotherapy regimens

S. Green, A. Pong, K. Jordan, 2018 .

Exploration of the heterogeneity of moderately emetogenic chemotherapy on response to fosaprepitant in a randomized phase 3 trial

S. Green, K. Jordan, B. Rapoport, 2016 .

Phase I-II trial of daily thalidomide in combination with docetaxel in patients with relapsed non-small cell lung cancer: A final analysis.

W. Walsh, J. Rooney, S. Khanani, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive serum cytokine analysis identi fi es IL-1RA and soluble IL-2R α as predictors of event-free survival in T-cell lymphoma

S. Green, K. Jordan, B. Rapoport, 2015 .

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

S. Green, A. Pong, K. Jordan, 2020, BMC Cancer.

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial

S. Green, A. Pong, K. Jordan, 2018, Supportive Care in Cancer.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

S. Green, A. Pong, K. Jordan, 2020, BMC Cancer.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

S. Green, K. Jordan, B. Rapoport, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

S. Green, A. Pong, K. Jordan, 2020, BMC Cancer.